Search

Displaying results 3701 - 3710 of 9705 in total
  1. Drug

    PF-04856884

    go.drugbank.com/drugs/DB17550
    Investigational

    PF-04856884 or CVX-060 is a selective angiopoietin (Ang)-2 inhibitor.

  2. Drug

    Pucotenlimab

    go.drugbank.com/drugs/DB17552
    ApprovedInvestigational

    Pucotenlimab is a recombinant humanized anti-PD-1 monoclonal antibody. It received its first global approval in China in July 2022 for the treatment of solid tumours.

  3. Drug

    PF-08046040

    go.drugbank.com/drugs/DB17555
    Investigational

    SEA-CD70 is under investigation in clinical trial NCT04227847 (A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies).

  4. Drug

    Rineterkib

    go.drugbank.com/drugs/DB17560
    Investigational

    Rineterkib is an inhibitor of extracellular signal-regulated kinase (ERK) being investigated in NCT04097821 (A Randomized, Open-label, Phase I/II Open Platform Study Evaluating Safety and Efficacy of Novel

  5. Drug

    Polyvalent antigen-KLH conjugate vaccine

    go.drugbank.com/drugs/DB17565
    Investigational

    Polyvalent antigen-KLH conjugate vaccine is a multivalent cancer vaccine comprised of the five tumor-associated antigens (TAAs) globo H, GM2 ganglioside, Tn-MUC1, TF, and sTn conjugated with the immunoadjuvant

  6. Drug

    Utidelone

    go.drugbank.com/drugs/DB17575
    Investigational

    Utidelone (UTD1), a novel microtubule stabilizing agent, is an epothilone B analogue produced by genetic engineering.[A257544,A257549] It is under investigation in clinical trials for various cancers.

  7. Drug

    ABBV-514

    go.drugbank.com/drugs/DB17586
    Investigational

    ABBV-514 is in development for the treatment of non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) as a single agent and in combination with a PD-1 inhibitor.[L45464]

  8. Drug

    Rocapuldencel-T

    go.drugbank.com/drugs/DB17588
    Investigational

    Rocapuldencel-T is an autologous dendritic cell immunotherapy that was investigated in NCT02662634 (A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer

  9. Drug

    NTLA-2002

    go.drugbank.com/drugs/DB17597
    Investigational

    NTLA-2002 is a lipid nanoparticle encapsulating single guide RNA (G012267) targeting the human KLKB1 gene and messenger RNA (mRNA000042) encoding Cas9.

  10. Drug

    Emprumapimod

    go.drugbank.com/drugs/DB17603
    Investigational

    Emprumapimod is a potent, orally active and selective inhibitor of p38α mitogen-activated kinase inhibitor. It was investigated for dilated cardiomyopathy.